Jean-Michel Cossery Buys Shares of SOPHiA GENETICS SA $SOPH
Key Points
- Jean-Michel Cossery bought 28,818 shares of SOPHiA GENETICS SA ($SOPH) worth $157,346.28.
- $SOPH last traded around $5.34.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jean-Michel Cossery, insider at SOPHiA GENETICS SA ($SOPH), bought 28,818 shares at an average price of $5.46, for a total transaction of $157,346.28. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
SOPHiA GENETICS SA Stock Down 34.4%
Shares of SOPHiA GENETICS SA ($SOPH) traded around $5.34 on Tuesday, down 34.4% for the day.
SOPHiA GENETICS SA Earnings
Analysts Set New Price Targets
About SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Get SOPHiA GENETICS SA alerts
New 13F filings, insider trades, and analyst moves on $SOPH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.